× Copyright Disclaimer Privacy Policy Author Guidelines Current Issue Archive Publishing Ethics Join As Reviewer Advertise Submit Article Abstracting And Indexing Editorial Board Contact Editor-in-Chief Scope of the Journal About the Journal


JAPER is indexed in SCOPUS

Views: 970 Downloads: 116

Efficacy and safety of vigabatrin as an initial therapy for tuberous sclerosis-associated infantile spasms


, , , , ,

Abstract

Tuberous sclerosis Complex (TSC) is a genetic disorder characterized by the formation of benign tumors in multiple organs, including the brain. Infantile spasms (IS) are a common seizure type that can occur in children with TSC and can lead to developmental delays and cognitive impairment if left untreated. Vigabatrin is an antiepileptic drug that has been shown to be effective in treating IS, but its efficacy and safety in TSC-afflicted children are not well understood. Our study intended to investigate the efficacy and safety of vigabatrin in treating infantile spasms in children with tuberous sclerosis. A retrospective analysis of medical records was conducted in a tertiary hospital and identified 25 children with tuberous sclerosis who had been diagnosed with infantile spasms and treated with vigabatrin. We found that vigabatrin was effective in controlling infantile spasms in 84% of patients, with a significant reduction in seizure frequency and improvement in developmental outcomes. However, we also observed a high incidence of adverse events, particularly visual field defects. Our study highlights the potential benefits and risks of vigabatrin as a treatment option for infantile spasms in children with tuberous sclerosis and underscores the importance of careful monitoring for adverse effects. More investigation is required to improve the understanding of the drug’s long-term safety and efficacy in this population.


How to cite this article:
Vancouver
Zeka N, Jashari H, Bejiqi R, Zeka B, Zogaj L, Maloku A. Efficacy and safety of vigabatrin as an initial therapy for tuberous sclerosis-associated infantile spasms. J Adv Pharm Educ Res. 2023;13(2):124-7. https://doi.org/10.51847/aOyVGONwGi
APA
Zeka, N., Jashari, H., Bejiqi, R., Zeka, B., Zogaj, L., & Maloku, A. (2023). Efficacy and safety of vigabatrin as an initial therapy for tuberous sclerosis-associated infantile spasms. Journal of Advanced Pharmacy Education and Research, 13(2), 124-127. https://doi.org/10.51847/aOyVGONwGi
Citation Formats:


Contact SPER Publications


SPER Publications and Solutions Pvt. Ltd.

HD - 236,
Near The Shri Ram Millenium School,
Sector 135,
Noida-Greater Noida Expressway,
Noida-201301 [Delhi-NCR] India